Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Finished Goods: 2024-2025

  • Day One Biopharmaceuticals' Finished Goods was N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $873,000 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Finished Goods stood at $1.1 million, which was down 24.03% from $1.4 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Finished Goods' 5-year high stood at $1.4 million during Q2 2025, with a 5-year trough of $873,000 in Q4 2024.
  • In the last 2 years, Day One Biopharmaceuticals' Finished Goods had a median value of $1.1 million in 2025 and averaged $1.1 million.